ECSP088689A - NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS - Google Patents

NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS

Info

Publication number
ECSP088689A
ECSP088689A EC2008008689A ECSP088689A ECSP088689A EC SP088689 A ECSP088689 A EC SP088689A EC 2008008689 A EC2008008689 A EC 2008008689A EC SP088689 A ECSP088689 A EC SP088689A EC SP088689 A ECSP088689 A EC SP088689A
Authority
EC
Ecuador
Prior art keywords
novedosas
hidroxiandrosta
onas
hydroxyandrosta
antiallergic
Prior art date
Application number
EC2008008689A
Other languages
English (en)
Inventor
Jiten Ranchhodbhai Patel
Gopalkumar Chimanlal Patel
Gaurav Sanjivkumar Sheth
Samir Rameshchandra Shah
Sanjay Nandlal Mandhane
Trinadha Rao Chitturi
Rajamannar Thennati
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of ECSP088689A publication Critical patent/ECSP088689A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a análogos anti-inflamatorios y antialérgicos novedosos de las 11ß-hidroxiandrosta-4-en-3-onas, representados como fórmula I y su sal fisiológicamente aceptable, que tienen efectos sistémicos insignificantes o no dignos de mención con múltiplos de una dosis eficaz.
EC2008008689A 2006-01-27 2008-08-21 NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS ECSP088689A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN131MU2006 2006-01-27

Publications (1)

Publication Number Publication Date
ECSP088689A true ECSP088689A (es) 2008-11-27

Family

ID=38459436

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008689A ECSP088689A (es) 2006-01-27 2008-08-21 NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS

Country Status (21)

Country Link
US (1) US8785425B2 (es)
EP (1) EP2004667B1 (es)
JP (1) JP5097129B2 (es)
KR (1) KR101390272B1 (es)
CN (1) CN101384610B (es)
AP (1) AP2642A (es)
AR (1) AR059216A1 (es)
AU (1) AU2007220114B2 (es)
BR (1) BRPI0706767A2 (es)
CA (1) CA2637548C (es)
EA (1) EA017490B9 (es)
EC (1) ECSP088689A (es)
ES (1) ES2428066T3 (es)
IL (1) IL192983A (es)
MX (1) MX2008009173A (es)
NZ (1) NZ569867A (es)
SG (1) SG170049A1 (es)
TW (1) TWI374147B (es)
UA (1) UA95095C2 (es)
WO (1) WO2007099548A2 (es)
ZA (1) ZA200806366B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
AU2013202835B2 (en) * 2006-06-14 2015-11-12 Generics [Uk] Limited Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1, 4-diene-17-carbothioate and intermediates
PL2044099T3 (pl) * 2006-06-14 2012-10-31 Generics Uk Ltd Sposób wytwarzania S-fluorometylo-6,9-difluoro-11-hydroksy-16-metylo-17-propionyloksy-3-okso-androsta-1,4-dieno-17-karbotionianu oraz związki pośrednie
EP2435462A1 (en) 2009-05-29 2012-04-04 Pfizer Limited Novel glucocorticoid receptor agonists
CA2796963A1 (en) 2010-04-23 2011-10-27 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
KR101103943B1 (ko) * 2011-12-12 2012-01-12 오수련 무료이용쿠폰을 활용한 제휴사 및 리셀러의 온라인 제휴마케팅 운영방법
WO2013133980A1 (en) * 2012-03-05 2013-09-12 Bausch & Lomb Incorporated Nitroxy derivatives of soft steroids
US9844599B2 (en) 2013-01-21 2017-12-19 Apparao Satyam Nitric oxide releasing produgs of therapeutic agents
MY179214A (en) * 2013-05-28 2020-11-02 Sun Pharma Advanced Res Co Ltd Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6alpha, 9alpha- difluoro-17alpha-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha- methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法
CN109438543B (zh) * 2018-11-28 2020-09-15 广州健康元呼吸药物工程技术有限公司 一种高纯度糠酸氟替卡松的制备方法
CN111662353A (zh) * 2019-03-05 2020-09-15 上海谷森医药有限公司 一种糠酸氟替卡松晶型1的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US300792A (en) * 1884-06-24 John asbeeey nicholson
US392976A (en) * 1888-11-13 Support for spinning-spindles
US3007923A (en) 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
ZA814440B (en) * 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
US6610675B1 (en) * 1980-07-10 2003-08-26 Nicholas S. Bodor Inactive metabolite approach to soft drug design
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
TR199801247T2 (xx) * 1995-12-29 1998-11-23 Glaxo Group Limited 17.beta.-karboksi, karbotio t�revleri ve amid androstan t�revleri.
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
WO1999001467A2 (en) 1997-06-30 1999-01-14 Glaxo Group Limited Therapeutically active compounds with low systemic activity due to reduce half life
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
WO2004001369A2 (en) 2002-06-20 2003-12-31 Sun Pharmaceutical Industries Limited Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas

Also Published As

Publication number Publication date
KR20080091813A (ko) 2008-10-14
CN101384610A (zh) 2009-03-11
CN101384610B (zh) 2013-07-17
KR101390272B1 (ko) 2014-05-19
ZA200806366B (en) 2009-08-26
EP2004667B1 (en) 2013-09-04
EP2004667A2 (en) 2008-12-24
AU2007220114B2 (en) 2011-11-10
WO2007099548A2 (en) 2007-09-07
EP2004667A4 (en) 2012-07-18
US8785425B2 (en) 2014-07-22
EA200801596A1 (ru) 2009-04-28
MX2008009173A (es) 2009-01-15
TWI374147B (en) 2012-10-11
SG170049A1 (en) 2011-04-29
EA017490B9 (ru) 2013-04-30
NZ569867A (en) 2011-06-30
AP2642A (en) 2013-04-15
UA95095C2 (en) 2011-07-11
AP2008004558A0 (en) 2008-08-31
IL192983A (en) 2014-06-30
JP2009524649A (ja) 2009-07-02
WO2007099548A3 (en) 2008-10-09
AU2007220114A1 (en) 2007-09-07
JP5097129B2 (ja) 2012-12-12
ES2428066T3 (es) 2013-11-05
EA017490B1 (ru) 2012-12-28
TW200804407A (en) 2008-01-16
US20090054388A1 (en) 2009-02-26
AR059216A1 (es) 2008-03-19
CA2637548C (en) 2014-09-23
CA2637548A1 (en) 2007-09-07
BRPI0706767A2 (pt) 2011-06-28
IL192983A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1119684T1 (el) Αντι-ιικες ενωσεις
DOP2012000011A (es) Formulacion farmaceutica
CR9230A (es) Uso de derivados del acido tetramico para el control de los insectos del genero de los hemipteros (sternorrhyncha)
SV2009003376A (es) Derivados de aril isoxazolinas insecticidas
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
BR112012021771A2 (pt) métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2.
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CR10383A (es) Derivados triazolopirazina.
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
NI201200168A (es) Formulaciones farmacéuticas
BRPI0606606A2 (pt) composições estáveis contendo prostaglandina
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
CO6741154A2 (es) Compuestos de triazolopiridina
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
CR20110219A (es) Ácidos naftilacéticos
ECSP109968A (es) Depsipéptidos cíclicos
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
DOP2011000335A (es) Combinacion antitumoral que comprende ave8062 y sorafenib
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas